Sapience Therapeutics

6 additional trials Clin2 multiple cancers; ST316 Clin1/Clin2 solid tumors; JunAP RD multiple cancers; FoxAP RD multiple cancers

Sapience Therapeutics is developing peptide therapeutics to provide new treatment options for cancer patients. Transcription factors are important proteins that control which genes are expressed within a cell. It is estimated that around 20% of oncogene mutations are found within transcription factors suggesting the proteins play an important role in oncogenesis. Sapience is using a tailored approach to drug transcription factors by disrupting protein-protein interactions (PPIs). Instead of using traditional modalities such as small molecules and antibodies that lack the properties to effectively target transcription factors, Sapience is creating their SPEAR peptides that can penetrate cell membranes, are non-immunogenic and can modulate PPIs.

Jobs: